Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.640
+0.147 (9.85%)
At close: Jul 31, 2026, 4:00 PM EDT
1.670
+0.030 (1.83%)
Pre-market: Aug 3, 2026, 6:58 AM EDT

Calidi Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
21384158581,3973,128
Market Cap Growth
-92.06%-66.78%-51.63%-38.56%-55.34%-
Enterprise Value
-2.38134.87412.99863.511,4113,357
Last Close Price
1.6418.72220.802899.2019526.4018835.20
PS Ratio
----31039.606966.38
PB Ratio
0.2536.69270.61-104.22-27.69-212.97
P/TBV Ratio
0.131.346.00---
EV/Sales Ratio
----31352.207476.27
Debt / Equity Ratio
0.150.281.32-0.65-0.040
Net Debt / Equity Ratio
-0.89-0.81-1.67-0.64-0.090.07
Net Debt / EBITDA Ratio
0.250.160.13-0.19-0.190.10
Net Debt / FCF Ratio
0.240.140.13-0.19-0.330.13
Asset Turnover
-0000.000.00
Quick Ratio
1.731.421.010.190.012.59
Current Ratio
1.921.591.080.420.023.61
Return on Equity (ROE)
-439.59%-700.65%708.76%119.07%-29.15%-5.08%
Return on Assets (ROA)
-210.12%-175.83%-180.07%-459.86%-19.75%-4.53%
Return on Invested Capital (ROIC)
-3018.88%-29786.98%---26.62%-4.90%
Return on Capital Employed (ROCE)
-362.74%-421.32%-973.66%142.80%-24.22%-4.53%
Buyback Yield / Dilution
-445.69%-544.98%----
Total Shareholder Return
-445.69%-544.98%----
SEC Filings: 10-K · 10-Q